Northway Biotech
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GA-ASI Gambit 6 UCAV Adds Air-To-Ground Operations for International CCA4.11.2025 16:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / The latest iteration of the innovative Gambit Series of unmanned combat air vehicles (UCAV) from General Atomics Aeronautical Systems, Inc. (GA-ASI) is Gambit 6, a collaborative combat aircraft (CCA) that adds air-to-ground operations to its already proven air-to-air capability. The multi-role platform is optimized for roles such as electronic warfare, suppression of enemy air defenses (SEAD), and deep precision strike, making it a versatile option for evolving defense needs. Air forces throughout the world are looking to air-to-ground-capable CCAs to enhance operational capabilities and address emerging threats in a denied environment. Gambit 6 is being developed to meet the corresponding need for adaptability, scalability, and mission-specific performance. "These are real threats, and they require real solutions," said GA-ASI President David R. Alexander. "The modular architecture and signature-reducing internal weapons bay
FiberCop and FMC GlobalSat/MTN Seal Strategic Partnership to Develop Hybrid Terrestrial-satellite Network Architectures in Italy4.11.2025 13:00:00 CET | Press release
The two companies have signed a strategic partnership aimed at offering high-speed connectivity across Italy, enabling high-performance backhaul and last-mile services by integrating satellite backhaul and fiber access in remote areas. ROME, ITALY AND FORT LAUDERDALE, FL / ACCESS Newswire / November 4, 2025 / FiberCop, the company running Italy's most advanced, extensive and widespread digital network infrastructure has signed a strategic partnership with FMC GlobalSat and its 100% owned subsidiary MTNSat "MTN", a world-class satellite network operator, to develop cutting-edge hybrid terrestrial-satellite solutions to deliver stable connectivity in remote areas across Italy. This agreement represents one of the first architectures of its kind developed worldwide over Low Earth Orbit (LEO) satellite networks. Altogether, both companies have successfully completed tests with hybrid network architectures that integrate LEO satellite services into terrestrial infrastructures, specifically
Sauce Labs Introduces Sauce AI for Insights: Purpose-Built AI Agents That Transform Software Quality Data Into Instant Engineering Intelligence3.11.2025 16:00:00 CET | Press release
Purpose-Built AI Agents Eliminate Hours of Manual Test Analysis, Accelerating Release Cycles and Empowering Engineering Teams to Ship High-Quality Applications with Unprecedented Speed and Confidence SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / Sauce Labs, the leading platform for continuous quality, today announced Sauce AI for Insights, a groundbreaking suite of AI-powered data and analytics capabilities that fundamentally transforms how engineering teams analyze, understand, and act on real-time test execution and runtime data to deliver quality releases at speed - while offering enterprise-grade rigorous security and compliance controls. As the industry's first AI agent purpose-built for software quality intelligence, Sauce AI for Insights converts one of the most critical bottlenecks in modern software development into a strategic advantage: the overwhelming volume of test data that slows decision-making and delays releases now accelerates developer productivity and en
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of FLSmidth Cement from FLSmidth & Co. A/S3.11.2025 16:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / November 3, 2025 / Pacific Avenue Capital Partners ("Pacific Avenue"), a leading global private equity firm focused on corporate carve-outs and other complex situations in the middle market, today announced it has completed the acquisition of FLSmidth Cement A/S ("FLSmidth Cement" or "Company"), from FLSmidth & Co. A/S (CPH:FLS) ("FLSmidth"). With the completion of the transaction, FLSmidth Cement will operate under the new name Fuller Technologies ("Fuller"), marking the beginning of its next chapter as an independent, technology-driven leader serving the global cement sector. Fuller is a leading solutions provider for the cement production industry focused on providing aftermarket parts and services to as well as new and replacement equipment for cement plants around the globe. The Company has manufacturing locations in North America, Europe, and Asia, and its global installed base spans over 1,400 of the world's approximate 2,700 cement plants. Wi
Scam Encounters Every Four Days: Mexico's Financial Toll3.11.2025 13:00:00 CET | Press release
This study of 1,000 Mexican adults reveals that over three-quarters have encountered a scam, with an average of one scam encounter happening every four days, equating to 86 scam encounters on average per person per year in Mexico. THE HAGUE, NL / ACCESS Newswire / November 3, 2025 / Additionally, nearly 3/5 of Mexican adults claim to have experienced a scam in the last year, with each scam victim being scammed on average 1.8 times. With widespread financial losses Shopping scams (55%), investment scams (48%) and unexpected money scams (47%) are the most common types of scams in Mexico, with some having money stolen via email while others received kidnapping threats. Additionally, over 1/3 of Mexican adults claim to have lost money to scams in the last year. Wire or bank transfers (55%) and debitcard payments (21%) are the most common methods used by scammers to receive payment. Of those who have experienced being scammed, 2/3 have reported the scam to the payment service, and half of t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom